Clinical trials: Immune Dysfunction
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer.
- Trial name
- NCT00604175
- Testing
- Quadrivalent HPV vaccine
- Where
- 61 sites in United States, Brazil and 2 more
- Volunteers
- 319 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Follicular Lymphoma
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to determine the rate and duration of complete remission and molecular response in patients with relapsed/refractory follicular lymphoma, using a combined treatment with rituximab plus chemotherapy…
- Trial name
- NCT00366275
- Testing
- Immunochemotherapy, in vivo purging and autrotransplant
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Rheumatoid Arthritis
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, pain, stiffness, damage, and ultimately loss of joint function.
- Trial name
- NCT00396812
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumor, Multiple Myeloma
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion.
- Trial name
- NCT00701103
- Testing
- Dalotuzumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the…
- Trial name
- NCT04270942
- Testing
- teplizumab 1 mg/mL
- Where
- 8 sites in United States
- Volunteers
- 6 people
- Sponsor
- Provention Bio, a Sanofi Company
Asthma
Effect of Anti-IgE in Non-Allergic Asthma
The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.
- Trial name
- NCT00162773
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating patients with Waldenstrom macroglobulinemia that is newly diagnosed, has come back…
- Conditions
- Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03506373
- Testing
- Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Asthma
Clinical Study to Evaluate Z7200 Pharmacokinetics Profile
Brief Summary: The primary objective was: to assess the bioequivalence of a single dose (two inhalations) of the test product compared to the reference product, with and without charcoal blockade.
- Trial name
- NCT02631941
- Testing
- Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Autoimmune Diseases
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
GSK2982772 is a first-in-class, highly selective, receptor-interacting protein-1 (RIP1) kinase inhibitor being developed for the treatment of inflammatory bowel disease, plaque psoriasis (PsO), rheumatoid arthritis (RA) and other…
- Trial name
- NCT03266172
- Testing
- GSK2982772 Modified Release, GSK2982772 Immediate Release
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
B-cell Non-Hodgkin Lymphoma
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
This is an open-label extension study enrolling participants experiencing clinical benefit following 6 cycles of DI-Leu16-IL2 while enrolled in the Alopexx Oncology Dose-Escalation AO-101 study (NCT01874288).
- Trial name
- NCT02151903
- Testing
- DI-Leu16-IL2
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alopexx Oncology, LLC
HIV Infections
R5 Integrase Study in HIV-1 Naive Patients
This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients.
- Trial name
- NCT01204905
- Testing
- Raltegravir and Maraviroc in combination
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
Type 1 Diabetes
Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes
Up to 40% of adults with type 1 diabetes have insufficient sleep which is associated with negative health consequences including poor blood glucose control and greater diabetes complications.
- Trial name
- SOPT (NCT04506151)
- Testing
- Sleep-Opt, Healthy Living
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Illinois at Chicago
HIV Testing, HIV Infections
OraQuick® HIV Self-Test Study in Canada
Oral fluid based HIV Self-testing (HIVST) provides another innovative and simple option to increase opportunities for HIV testing.
- Trial name
- OQHIVST (NCT05020353)
- Testing
- OraQuick® HIV Self-Test
- Where
- 7 sites in Canada
- Volunteers
- 951 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Atopic Dermatitis, Atopic Dermatitis Eczema
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
- Trial name
- NCT03293030
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
HIV Infections
Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy
The purpose of this study was to evaluate the safety and antiviral activity to promote clearance of HIV-1 infected cells of VRC01 in infants with HIV beginning combination antiretroviral therapy (cART).
- Trial name
- NCT03208231
- Testing
- VRC01, Combination Antiretroviral Therapy (cART)
- Where
- 7 sites in Botswana, Brazil and 2 more
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphocytic Leukemia, Chronic
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
- Trial name
- NCT02533401
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 9 sites in Argentina, Venezuela
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
1. To assess the baseline (i.e. RA therapy initiation) characteristics in a real-world setting across two moderate RA cohorts: a Test Group of patients newly exposed to etanercept (Enbrel) therapy and a Control Group of patients…
- Trial name
- NCT01557322
- Testing
- etanercept, methotrexate (MTX)
- Volunteers
- 1,754 people
- Sponsor
- Pfizer
Perennial Allergic Rhinitis
The Role of Montelukast in Rhinitis and Sleep
The hypothesis is that a leukotriene receptor antagonist (LRA), montelukast, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round…
- Trial name
- NCT00590772
- Testing
- montelukast
- Volunteers
- 31 people
- Sponsor
- Penn State University
Allergic Rhinitis
Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic rhinitis (AR) is a disorder that affects more than 500 million people worldwide. Nasal congestion is one of the most general and bothersome symptoms in rhinitis, which impacts the quality of life (QOL).
- Trial name
- ANCAR (NCT05709977)
- Testing
- Acupuncture, Antihistamine nasal spray
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Johanna Maria Vermeulen